Abstract
The use of ultra-short-acting barbitu rates for intravenous anesthesia has be come increasingly popular in the office practice of oral surgery. Up to now, thiopental sodium has been the agent most extensively employed for this pur pose. The present report is concerned with a clinical evaluation of the use in oral surgery of a new agent of the thiobarbiturate group, thiamylal sodium (Surital) , 1 which, when judged by the reports of clinical studies of its use in general anesthesia, 2' 7 has proved to have several advantages over thiopental so dium. Chief among the advantages are the rapid induction and recovery and the low incidence of laryngospasm, respira tory depression, hypotension, and post operative nausea and vomiting. For these reasons, thiamylal sodium seems to be a more satisfactory agent for office use. The following studies were conducted in arder to evaluate it for this purpose.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
